[1] 张之南, 沈悌. 血液病诊断及疗效标准[M]. 3版. 北京: 科学出版社, 2007.
[2]

WATANABE N, NARIMATSU H, NOH J Y, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves' disease[J]. J Clin Endocrinol Metab,2012,97(1):E49-E53. doi:  10.1210/jc.2011-2221
[3]

YANG J, ZHU Y J, ZHONG J J, et al. Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years[J]. Thyroid,2016,26(5):627-633. doi:  10.1089/thy.2015.0439
[4] 于红专. 复方甘草合剂致血小板减少性紫癜并脑出血1例报告[J]. 中国中医急症, 2006, 15(5):450. doi:  10.3969/j.issn.1004-745X.2006.05.076
[5] 李岚, 夏东胜, 田春华, 等. 甲巯咪唑片安全性风险的分析及思考[J]. 中国药物警戒, 2018, 15(7):393-397. doi:  10.3969/j.issn.1672-8629.2018.07.003
[6] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11):1752-1769. doi:  10.3969/j.issn.1001-5256.2015.11.002
[7]

ROSS D S, BURCH H B, COOPER D S, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid,2016,26(10):1343-1421. doi:  10.1089/thy.2016.0229
[8] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南—甲状腺功能亢进症[J]. 中华内科杂志, 2007, 46(10):876-882.
[9] 中华医学会血液学分会, 中国医师协会血液科医师分会. 中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2016年版)[J]. 中华血液学杂志, 2016, 37(5):353-359. doi:  10.3760/cma.j.issn.0253-2727.2016.05.001
[10]

SMITH T J, KHATCHERESSIAN J, LYMAN G H, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline[J]. J Clin Oncol,2006,24(19):3187-3205. doi:  10.1200/JCO.2006.06.4451
[11]

WANG Y H, LI X Y, YANG Q, et al. Granulocyte-colony-stimulating factor effectively shortens recovery duration in anti-thyroid-drug-induced agranulocytosis: a systematic review and meta-analysis[J]. Front Endocrinol (Lausanne),2019,10:789. doi:  10.3389/fendo.2019.00789
[12] 中国临床肿瘤学会指南工作委员会. 肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J]. 中华肿瘤杂志, 2017, 39(11):868-878. doi:  10.3760/cma.j.issn.0253-3766.2017.11.011
[13]

ANDRÈS E, MALOISEL F, ZIMMER J. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis[J]. Br J Haematol,2010,150(1):3-8.
[14]

TAJIRI J, NOGUCHI S. Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy?[J]. Thyroid, 2005, 15(3): 292-297.
[15]

JIN J G, GAO X Y, ZHANG W L. Treatment of methimazole-induced agranulocytosis with low-dose prednisone and ciclosporin following failed treatment with colony-stimulating factors[J]. Clin Endocrinol (Oxf),2010,73(3):422-424.
[16]

ANDRÈS E, ZIMMER J, MECILI M, et al. Clinical presentation and management of drug-induced agranulocytosis[J]. Expert Rev Hematol,2011,4(2):143-151. doi:  10.1586/ehm.11.12